Skip to Main content Skip to Navigation
Journal articles

Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies

Abstract : Over the past two decades, aspirin has emerged as a promising chemoprotective agent to prevent colorectal cancer (CRC). In 2016, the mounting evidence supporting its chemoprotective effect, from both basic science and clinical research, led the US Preventive Services Task Force to recommend regular use of low-dose aspirin in some subgroups of patients for whom the benefits are deemed to outweigh the risks. In contrast, data on the chemoprotective effect of aspirin against other cancers are less clear and remain controversial. Most data come from secondary analyses of cardiovascular prevention trials, with only a limited number reporting cancer outcomes as a prespecified endpoint, and overall unclear findings. Moreover, the potential chemoprotective effect of aspirin against other cancers has been recently questioned with the publication of 3 long-awaited trials of aspirin in the primary prevention of cardiovascular diseases reporting no benefit of aspirin on overall cancer incidence and cancer-related mortality. Data on the chemoprotective effects of other antiplatelet agents remain scarce and inconclusive, and further research to examine their benefit are warranted. In this narrative review, we summarize current clinical evidence and continuing controversies on the potential chemoprotective properties of antiplatelet agents against cancer.
Complete list of metadatas

Cited literature [96 references]  Display  Hide  Download

https://hal.sorbonne-universite.fr/hal-02426511
Contributor : Gestionnaire Hal-Su <>
Submitted on : Thursday, January 2, 2020 - 3:00:32 PM
Last modification on : Friday, March 27, 2020 - 3:19:18 AM

File

cancers-11-01639.pdf
Publication funded by an institution

Identifiers

Citation

Corinne Frere, Manon Lejeune, Pierre Kubicek, Dorothée Faille, Zora Marjanovic. Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. Cancers, MDPI, 2019, 11 (11), pp.1639. ⟨10.3390/cancers11111639⟩. ⟨hal-02426511⟩

Share

Metrics

Record views

81

Files downloads

220